ArticleBMC cancer2025
Association of the YTHDF2 rs3738067 A>G variant with hepatoblastoma risk: a multicenter case-control study in Chinese children.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAs a rare cancer, hepatoblastoma is the most prevalent malignant liver tumor in children, yet its underlying causes are poorly understood. YTHDF2, a canonical m⁶A reader, regulates mRNA stability and decay, and its dysregulation has been implicated in tumorigenesis across multiple malignancies. Whether YTHDF2 polymorphisms influence hepatoblastoma risk is unclear. This multicenter case-control study was therefore designed to analyze the YTHDF2 rs3738067 A > G variant in Chinese children.
methodsWe recruited 313 hepatoblastoma cases and 1446 controls from seven hospitals across China for this case-control study. The YTHDF2 rs3738067 A > G polymorphism was genotyped using the TaqMan PCR method. We assessed its association with hepatoblastoma risk using multivariate logistic regression to calculate adjusted odds ratios and 95% confidence intervals, controlling for age and sex.
resultsComprehensive analyses of this multi-center Chinese pediatric cohort revealed that the YTHDF2 rs3738067 A > G polymorphism was not associated with hepatoblastoma risk in any analysis, including the overall population and all stratified subgroups.
conclusionsThese findings suggest that this specific YTHDF2 variant may not be a key risk factor for hepatoblastoma in Chinese children. Future studies incorporating diverse ethnic populations and investigating other polymorphisms, alone or in combination, are warranted to confirm these findings and explore potential associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.